← FDA DRUG APPROVALS

FDA ANDA · ANDA078705

DIVALPROEX SODIUM

Sponsor: SCIEGEN PHARMS

APPLICATION
ANDA078705
TYPE
ANDA
ORIGINAL APPROVAL
2009-02-10
LATEST ACTION
2014-11-08
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

DIVALPROEX SODIUMPrescription
DIVALPROEX SODIUM EQ 500MG VALPROIC ACID · TABLET, EXTENDED RELEASE · ORAL
DIVALPROEX SODIUMPrescription
DIVALPROEX SODIUM EQ 250MG VALPROIC ACID · TABLET, EXTENDED RELEASE · ORAL

Approval history

2014-11-08Labeling · Supplement 5 · standardAP
2014-11-08Labeling · Supplement 6 · standardAP
2009-08-05Labeling · Supplement 4AP
2009-08-04Labeling · Supplement 3AP
2009-08-04Supplement · Supplement 1AP
2009-08-04Supplement · Supplement 2AP
2009-02-10OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →